tiprankstipranks
Silence Therapeutics’ Divesiran Shows Promise in PV Study
Company Announcements

Silence Therapeutics’ Divesiran Shows Promise in PV Study

Silence Therapeutics (SLN) has released an update.

Don't Miss our Black Friday Offers:

Silence Therapeutics has reported promising outcomes from its Phase 1 SANRECO study of divesiran in polycythemia vera patients, showing elimination of phlebotomy requirements in well-controlled individuals and a good safety profile. The data supports the progression of divesiran into Phase 2 trials. With its potential as the first siRNA therapy for this condition, divesiran demonstrates sustained reduction in hematocrit and favorable effects on iron metabolism indicators.

For further insights into SLN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlySilence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital
TheFlySILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes
TheFlySILENCE THERAPEUTICS PLC SPONSORED ADR trading halted, volatility trading pause
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App